Ocriplasmin Effective in Resolving VMT and Closing Macular Holes

ThromboGenics NV announced that the data from two phase 3 clinical trials evaluating ocriplasmin for the treatment of vitreomacular traction (VMT) and macular hole were published in the emNew England Journal of Medicine/em.sup1/sup The article highlights that a single intravitreal injection of ocriplasmin resolved vitr...

Full Story →